Partnership for Health: Microbix and ACPCC
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF), a leader in life sciences innovation, has joined forces with the Australian Centre for the Prevention of Cervical Cancer (ACPCC). This partnership is set to contribute significantly towards eliminating cervical cancer in the Indo-Pacific region, spearheaded by a recently signed Memorandum of Understanding (MOU) aimed at enhancing HPV testing quality.
The Amerging Crisis of Cervical Cancer
Despite being a largely preventable disease, cervical cancer remains a leading cause of mortality among women in the Indo-Pacific. The high-risk Human Papillomavirus (HPV) is responsible for most cervical cancer cases. Microbix’s PROCEEDx™FLOQ brand Quality Assessment Products (QAPs™) will play a crucial role in ensuring accurate HPV tests are accessible to populations at risk. This partnership, unveiled at a major health congress, marks a significant step towards improving diagnosis and treatment capabilities.
Understanding the EPICC Program
The Elimination Partnership in the Indo-Pacific for Cervical Cancer (EPICC) is a vital program designed to combat cervical cancer through enhanced screening and vaccination efforts. Supported by the Australian Government and philanthropic contributions, EPICC aims to improve prevention, early diagnosis, and effective treatment across multiple nations.
Expanding Reach and Impact
Currently, this initiative extends its reach to 12 countries, including Timor-Leste and the Solomon Islands, among others. The proven model has seen success in countries like Malaysia and Papua New Guinea, establishing a framework that can be replicated across the region. The goal is clear: to eliminate cervical cancer as a public health threat effectively.
Expert Commentary on the Collaboration
Dr. David Hawkes, a key figure in this initiative, emphasized the partnership’s potential. He stated, "Vaccination and screening are essential, yet many women in the Indo-Pacific remain at risk. Our collaboration with Microbix aims to make reliable molecular HPV tests widely available, which is critical to reducing cervical cancer incidence. Through QAPs, we can ensure that testing methods are accurate and consistent, bringing peace of mind to those screened."
Commitment to Quality Testing
Phil Casselli from Microbix highlighted the company's role in the initiative, stating that the firm is committed to providing top-tier products that guarantee test quality. The partnership aims to facilitate access to screenings for everyone, ensuring that timely and accurate tests are available for assessing HPV risk.
Microbix’s Contribution to Global Health
Microbix is renowned for its development of biological products crucial for health diagnostics. With more than 120 employees and ambitious monthly sales that are on the rise, the company focuses on manufacturing essential components for the global testing industry. Their products, which include antigens for immunoassays and QAPs, enhance clinical lab proficiency and ensure the quality of diagnostic workflows across more than 30 countries.
Recent Achievements and Future Prospects
Beyond cervical cancer, Microbix continues to innovate across various health fronts, including proprietary products for treating blood clots. The company’s commitment to quality and compliance is apparent through its multiple certifications, making it a trusted partner in global health initiatives.
About ACPCC and Its Vision
The Australian Centre for the Prevention of Cervical Cancer has been a leader in advancing public health initiatives for over six decades. Its goal is to eliminate cervical cancer through vaccination and robust screening programs, ensuring that individuals across the globe can live without the threat of this preventable disease.
Frequently Asked Questions
What is the role of Microbix in this partnership?
Microbix is supplying its Quality Assessment Products to enhance HPV test quality, contributing to the elimination of cervical cancer.
What does EPICC stand for?
EPICC stands for the Elimination Partnership in the Indo-Pacific for Cervical Cancer, which aims to improve cervical cancer prevention and treatment.
How many countries are involved in the EPICC program?
The EPICC program is currently expanding its impact to 12 countries in the Indo-Pacific region, focusing on vaccination and screening initiatives.
What are QAPs?
Quality Assessment Products (QAPs) are tools developed by Microbix to ensure the reliability and accuracy of diagnostic tests, particularly for HPV screenings.
Who can benefit from this initiative?
Women and individuals with a cervix in the Indo-Pacific region can benefit significantly from increased access to HPV testing and vaccination programs aimed at eliminating cervical cancer.
